Latest News

Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter




Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially, bringing in $186 million during the fourth quarter, topping analyst expectations on Wednesday.

Last June, Novartis secured U.S. approval for Zolgensma as a one-time treatment for spinal muscular atrophy, a rare and deadly neurological disease. It carries a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years.

Read the rest…

Source link




Related posts

Woman Suffers Skin Cancer 3 Decades After Contracting Chickenpox

Newsemia

Medical News Today: ¿Por qué siento dolor en mis talones y qué puedo hacer al respecto?

Newsemia

Medical News Today: Simple drug formula regenerates brain cells

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy